Mangrove Partners’s Haemonetics HAE Stock Holding History

Mangrove Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,371	Closed	-$1.2M	–	498
2026 Q1	$1.2M	Buy	21,371 +18,345	+606%	+$1.19M	0.1%	106
2025 Q4	$243K	Buy	+3,026	New	+$203K	0.02%	247

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mangrove Partners's HAE Position: Q2 2026 in Review

Mangrove Partners sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 21,371 shares — an estimated $1.2M sold.

Mangrove Partners first reported a position in HAE in Q4 2025 and held it in 2 quarters. The position peaked at $1.2M in Q1 2026. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Mangrove Partners reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
Mangrove Partners sold 21,371 Haemonetics shares in Q2 2026, an estimated $1.2M.
Mangrove Partners first reported a position in Haemonetics in Q4 2025 and held it in 2 quarters.
Mangrove Partners's Haemonetics position peaked at $1.2M in Q1 2026.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.